Composition and Formulation Details 3
Over four months on the medication, her weight decreased from 210.4 pounds to 181.8, a loss of 28.6 pounds, or 13.6% of her peak weight
Kesavardhana S, Malireddi R, Kanneganti TD
The FDA approved the medication to be used solely to treat individuals with type 2 diabetes
This is a common situation for many people with psoriasis, as these conditions often overlap
Initial studies, such as the SURMOUNT-1 clinical trial (Jastreboff et al., 2022), demonstrated significant weight reductions of between 15% and 22% of body weight in obese individuals, with or without diabetes, surpassing the results obtained with traditional GLP-1 analogs